Cowen and Company Reaffirms “Market Perform” Rating for TESARO Inc (TSRO)
Cowen and Company reiterated their market perform rating on shares of TESARO Inc (NASDAQ:TSRO) in a research report released on Sunday. Cowen and Company currently has a $145.00 price target on the biopharmaceutical company’s stock.
Several other analysts have also recently issued reports on TSRO. Citigroup Inc restated a buy rating and set a $216.00 target price (down from $232.00) on shares of TESARO in a research report on Saturday. Zacks Investment Research raised shares of TESARO from a sell rating to a hold rating in a research report on Friday, March 31st. FBR & Co reissued a buy rating on shares of TESARO in a research report on Thursday, January 12th. Credit Suisse Group AG set a $151.00 price objective on shares of TESARO and gave the stock a buy rating in a research report on Thursday, January 12th. Finally, Royal Bank of Canada increased their price objective on shares of TESARO from $142.00 to $202.00 and gave the stock an outperform rating in a research report on Friday, February 17th. Eight investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $165.81.
TESARO (NASDAQ:TSRO) traded down 2.16% during midday trading on Friday, reaching $136.01. The company had a trading volume of 743,982 shares. The company’s market capitalization is $7.29 billion. The firm has a 50-day moving average price of $154.31 and a 200-day moving average price of $144.64. TESARO has a 52 week low of $36.68 and a 52 week high of $192.94.
COPYRIGHT VIOLATION WARNING: “Cowen and Company Reaffirms “Market Perform” Rating for TESARO Inc (TSRO)” was originally reported by Marea Informative and is the property of of Marea Informative. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at http://www.mareainformativa.com/cowen-and-company-reaffirms-market-perform-rating-for-tesaro-inc-tsro/111775/.
In other news, VP Edward C. English sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $178.06, for a total transaction of $1,780,600.00. Following the transaction, the vice president now directly owns 5,396 shares of the company’s stock, valued at $960,811.76. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Martin H. Jr. Huber sold 829 shares of the firm’s stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $153.02, for a total transaction of $126,853.58. Following the transaction, the senior vice president now directly owns 6,522 shares in the company, valued at $997,996.44. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,432 shares of company stock worth $2,902,602. Corporate insiders own 40.50% of the company’s stock.
Several institutional investors have recently modified their holdings of TSRO. Capital Analysts LLC acquired a new position in TESARO during the fourth quarter worth about $134,000. Massmutual Trust Co. FSB ADV acquired a new position in TESARO during the fourth quarter worth about $134,000. Citizens Financial Group Inc RI acquired a new position in TESARO during the third quarter worth about $154,000. Pacer Advisors Inc. acquired a new position in TESARO during the third quarter worth about $216,000. Finally, Bank of Montreal Can increased its position in TESARO by 649.5% in the first quarter. Bank of Montreal Can now owns 2,286 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 1,981 shares in the last quarter. 98.48% of the stock is currently owned by institutional investors and hedge funds.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Stock Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related stocks with our FREE daily email newsletter.